Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Daysee is an extended-cycle combined oral contraceptive indicated for the prevention of pregnancy. It contains two hormones: levonorgestrel (a progestin) and ethinyl estradiol (an estrogen). Each 91-day pack consists of 84 tablets containing 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, followed by 7 tablets containing only 0.01 mg ethinyl estradiol[1][3]. The primary mechanism of action is suppression of ovulation; additional effects include thickening cervical mucus to inhibit sperm penetration and altering the endometrial lining to reduce the likelihood of implantation[2][5][6]. Besides contraception, Daysee may also be prescribed for acne management, reduction in ovarian cyst risk (such as in polycystic ovarian syndrome), treatment of heavy or painful periods, and menstrual regulation[5][6]. It does not protect against sexually transmitted infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Daysee.